This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Namenda XR

Allergan plc

Drug Names(s): memantine (Ebixa, Axura, SUN Y7017, Memary) XR

Description: Revenue splits for this drug are BioMedTracker estimates.

Memantine has been used in Germany for various forms of dementia for more than a decade. Memantine targets the NMDA glutamate receptor, whereas previously marketed anti-AD drugs target the enzyme acetylcholinesterase. Its mechanism of action is unclear, but persistent activation of central nervous system NMDA receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer's disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels.Namenda also showed antagonistic effects at the serotonin 5HT3 receptor with a potency similar to that for the NMDA receptor and blocked nicotinic acetylcholine receptors with one-sixth to one-tenth the potency.

Deal Structure: Memantine was originally developed by the private Germany company, Merz. In Europe, it is marketed by Lundbeck. In the U.S., Forest is developing memantine with help from Neurobiological Technologies (NTI). Memantine is under development in Japan by Merz's partner Suntory.

Merz and Neurobiological Technologies
In April 1998, NTI announced a strategic research and marketing alliance with Merz and a new revenue sharing partnership with the Children's Medical Center Corporation (CMCC) of Boston, Massachusetts, to further the development and commercialization of Memantine.

Under this new collaboration, CMCC will terminate its existing license to NTI for AIDS-related dementia and neuropathic pain and grant exclusive rights to Merz. In exchange, NTI will receive an up-front payment of $2.1 million from Merz. NTI and CMCC will now share in the revenues received from Memantine for neuropathic pain and AIDS dementia, as well as for dementia and Alzheimer's,...See full deal structure in Biomedtracker

Partners: Daiichi Sankyo Co., Ltd. H. Lundbeck A/S Merz Pharmaceuticals GmbH Adamas Pharmaceuticals, Inc.


Namenda XR News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug